{"Ticker": "ILMN", "Company": "Illumina", "Sector": "Health Care", "Updated": "2022-07-13", "Rating": [{"Date": "2022-07-13", "Rating": "Downgrade", "Organization": "Barclays", "Rating_Change": "Equal Weight to Underweight", "Target_Change": "$350 to $150"}, {"Date": "2022-01-18", "Rating": "Upgrade", "Organization": "Stifel", "Rating_Change": "Hold to Buy", "Target_Change": "$480"}, {"Date": "2022-01-11", "Rating": "Upgrade", "Organization": "Barclays", "Rating_Change": "Underweight to Equal Weight", "Target_Change": ""}, {"Date": "2022-01-07", "Rating": "Upgrade", "Organization": "BofA Securities", "Rating_Change": "Underperform to Neutral", "Target_Change": ""}, {"Date": "2022-01-06", "Rating": "Resumed", "Organization": "Piper Sandler", "Rating_Change": "Overweight", "Target_Change": "$450"}, {"Date": "2022-01-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$425"}, {"Date": "2021-10-15", "Rating": "Resumed", "Organization": "Cowen", "Rating_Change": "Outperform", "Target_Change": "$550"}, {"Date": "2021-08-19", "Rating": "Downgrade", "Organization": "SVB Leerink", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": "$425"}, {"Date": "2021-06-01", "Rating": "Upgrade", "Organization": "Evercore ISI", "Rating_Change": "Underperform to In-line", "Target_Change": "$400"}, {"Date": "2021-03-31", "Rating": "Upgrade", "Organization": "Canaccord Genuity", "Rating_Change": "Hold to Buy", "Target_Change": "$445"}, {"Date": "2021-03-31", "Rating": "Downgrade", "Organization": "Atlantic Equities", "Rating_Change": "Overweight to Neutral", "Target_Change": "$390"}, {"Date": "2021-03-03", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Underweight", "Target_Change": "$325"}, {"Date": "2020-12-22", "Rating": "Upgrade", "Organization": "Piper Sandler", "Rating_Change": "Neutral to Overweight", "Target_Change": "$340 to $415"}, {"Date": "2020-12-17", "Rating": "Upgrade", "Organization": "BTIG Research", "Rating_Change": "Neutral to Buy", "Target_Change": "$410"}, {"Date": "2020-10-13", "Rating": "Downgrade", "Organization": "Guggenheim", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2020-09-30", "Rating": "Initiated", "Organization": "Atlantic Equities", "Rating_Change": "Overweight", "Target_Change": "$355"}, {"Date": "2020-09-29", "Rating": "Downgrade", "Organization": "Wolfe Research", "Rating_Change": "Outperform to Peer Perform", "Target_Change": ""}, {"Date": "2020-09-22", "Rating": "Downgrade", "Organization": "UBS", "Rating_Change": "Buy to Neutral", "Target_Change": "$390 to $285"}, {"Date": "2020-09-22", "Rating": "Downgrade", "Organization": "Stifel", "Rating_Change": "Buy to Hold", "Target_Change": "$380 to $280"}, {"Date": "2020-09-21", "Rating": "Upgrade", "Organization": "Guggenheim", "Rating_Change": "Neutral to Buy", "Target_Change": "$345"}, {"Date": "2020-09-21", "Rating": "Downgrade", "Organization": "JP Morgan", "Rating_Change": "Overweight to Neutral", "Target_Change": "$390 to $280"}, {"Date": "2020-09-09", "Rating": "Initiated", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$400"}, {"Date": "2020-08-07", "Rating": "Downgrade", "Organization": "Piper Sandler", "Rating_Change": "Overweight to Neutral", "Target_Change": "$356 to $340"}, {"Date": "2020-08-07", "Rating": "Downgrade", "Organization": "Evercore ISI", "Rating_Change": "In-line to Underperform", "Target_Change": "$310"}, {"Date": "2020-07-07", "Rating": "Downgrade", "Organization": "Guggenheim", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2020-04-24", "Rating": "Downgrade", "Organization": "Citigroup", "Rating_Change": "Buy to Neutral", "Target_Change": "$250 to $320"}]}